Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan

Hsiu-Ling Huang, Pei-Tseng Kung, Chang-Fang Chiu, Yueh-Hsin Wang, Wen-Chen Tsai, Hsiu-Ling Huang, Pei-Tseng Kung, Chang-Fang Chiu, Yueh-Hsin Wang, Wen-Chen Tsai

Abstract

Background: Lung cancer is the leading cause mortality among all cancers in Taiwan. Although Taiwan offers National Health Insurance (NHI), occasionally, patients refuse treatment. This study examined the patient characteristics and factors associated with lung cancer patients refusing cancer treatment in four months after cancer diagnosed and compared the survival differences between treated and non-treated patients.

Methods: The study included 38584 newly diagnosed lung cancer patients between 2004 and 2008, collected from the Taiwan Cancer Registry, which was linked with NHI research database and Cause of Death data set. Logistic regression was conducted to analyze factors associated with treatment refusal. The Cox proportional hazards model was used to examine the effects of treatment and non-treatment on patient survival and the factors affecting non-treatment patient survival.

Results: Among the newly diagnosed cancer patients, older adults, or those who had been diagnosed with other catastrophic illnesses, an increased pre-cancer Charlson Comorbidity Index (CCI) score, and advanced stage cancer exhibited an increased likelihood of refusing treatment. Compared with treated patients, non-treated patients showed an increased mortality risk of 2.09 folds. The 1-year survival rate of treated patients (53.32%) was greater than that of non-treated patients (21.44%). Among the non-treated patients, those who were older, resided in lowly urbanized areas, had other catastrophic illnesses, a CCI score of ≥4, advanced cancer, or had received a diagnosis from a private hospital exhibited an increased mortality risk.

Conclusions: Despite Taiwan's NHI system, some lung cancer patients choose not to receive cancer treatment and the mortality rate for non-treated patients is significantly higher than that of patients who undergo treatment. Therefore, to increase the survival rate of cancer patients, treatment refusal should be addressed.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Survival curve using Cox proportional…
Figure 1. Survival curve using Cox proportional hazards model.
After controlling for the other variables, the mortality risk of lung cancer patients refusing treatment was 2.09 times (95% CI 2.03–2.14) that of those receiving treatment.

References

    1. World Health Organization (2008) Cancer mortality and morbidity. Available: . Accessed 2014 Jan 12.
    1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians 63: 11–30.
    1. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, et al. (2013) Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. Thorax 68: 551–564.
    1. Taiwan National Health Insurance Administration MoHW (2013) Statistics & Surveys. Available: . Accessed 2013 May 5.
    1. Taiwan Cancer Registry (2008) Cancer Statistics. Available: . Accessed 2013 May 19.
    1. Tsai W-C (2012) Exploring the reasons of non-treatment for cancer patients in Taiwan. Health Promotion Administration, Ministry of Health and Welfare (Project number: DOH 101-HP-1501).
    1. Wang B-Y, Huang J-Y, Cheng C-Y, Lin C-H, Ko J-L, et al. (2013) Lung cancer and prognosis in taiwan: a population-based cancer registry. Journal of Thoracic Oncology 8: 1128–1135.
    1. Khakwani A, Rich AL, Tata LJ, Powell HA, Stanley RA, et al. (2014) Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit. PloS one 9: e89426.
    1. Chi A, Liao Z, Nguyen NP, Xu J, Welsh JS, et al. (2012) Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. PloS one 7: e35809.
    1. Hedestig O, Sandman PO, Widmark A (2003) Living with untreated localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nurs 26: 55–60.
    1. Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Galanos A, et al. (2007) Depression, hopelessness, and sleep in cancer patients' desire for death. Int J Psychiatry Med 37: 201–211.
    1. Shubha R (2007) Psychosocial issues in end-of life care. J Psychosoc Nurs Ment Health Serv 45: 24–29.
    1. Lee-Chiong T Jr, Matthay R (1993) Lung cancer in the elderly patient. Clinics in chest medicine 14: 453–478.
    1. Brown J, Eraut D, Trask C, Davison A (1996) Age and the treatment of lung cancer. Thorax 51: 564–568.
    1. Ou SHI, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112: 2011–2020.
    1. Lu J-FR, Hsiao WC (2003) Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Affairs 22: 77–88.
    1. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of clinical epidemiology 45: 613–619.
    1. Radley A, Payne S (2009) A sociological commentary on the refusal of treatment by patients with cancer. Mortality 14: 309–324.
    1. Konigsberg RD (2011) Refuseniks. Why some cancer patients reject their doctor's advice. Time 177: 72–74, 77.
    1. Janssen-Heijnen ML, Smulders S, Lemmens V, Smeenk FW, Van Geffen H, et al. (2004) Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59: 602–607.
    1. Chadha AS, Ganti AK, Sohi JS, Sahmoun AE, Mehdi SA (2005) Survival in untreated early stage non-small cell lung cancer. Anticancer Res 25: 3517–3520.
    1. van Kleffens T, van Baarsen B, van Leeuwen E (2004) The medical practice of patient autonomy and cancer treatment refusals: a patients' and physicians' perspective. Social science & medicine (1982) 58: 2325–2336.
    1. Huchcroft SA, Snodgrass T (1993) Cancer patients who refuse treatment. Cancer Causes & Control 4: 179–185.
    1. Lin JH, Zhang SM, Manson JE (2011) Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila) 4: 1360–1365.
    1. Marshall CA, Badger TA, Curran MA, Koerner SS, Larkey LK, et al. (2013) Un Abrazo Para La Familia: Providing low-income Hispanics with education and skills in coping with breast cancer and caregiving. Psycho-Oncology 22: 470–474.
    1. Turner D, Adams E, Boulton M, Harrison S, Khan N, et al. (2013) Partners and close family members of long-term cancer survivors: health status, psychosocial well-being and unmet supportive care needs. Psycho-Oncology 22: 12–19.
    1. Ferguson MK, Skosey C, Hoffman PC, Golomb HM (1990) Sex-associated differences in presentation and survival in patients with lung cancer. Journal of Clinical Oncology 8: 1402–1407.
    1. Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, et al. (2000) Sex-associated differences in survival of patients undergoing resection for lung cancer. The Annals of thoracic surgery 69: 245–249.
    1. Ökten SY (2003) Female and male differences in the survival of patients undergoing resection for lung cancer. Acta chir belg 103: 293–296.
    1. Warnakulasuriya S, Mak V, Moller H (2007) Oral cancer survival in young people in South East England. Oral Oncol 43: 982–986.
    1. Yim J, Hwang SS, Yoo KY, Kim CY (2012) Contribution of income-related inequality and healthcare utilisation to survival in cancers of the lung, liver, stomach and colon. J Epidemiol Community Health 66: 37–40.
    1. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, et al. (2003) Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 106: 416–422.
    1. Ma H, Shu Y, Pan S, Chen J, Dai J, et al. (2011) Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer 74: 164–169.
    1. Simon TG, Beland MD, Machan JT, DiPetrillo T, Dupuy DE (2012) Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. European Journal of Radiology.
    1. Kowalski L, Carvalho A (2000) Natural history of untreated head and neck cancer. European Journal of Cancer 36: 1032–1037.
    1. Chen CY-C (2011) TCM Database@ Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PloS one 6: e15939.
    1. Chu F-YS (2012) Complementary and Alternative Medicine Use and Quality of Life in Chinese Women with Breast Cancer: A Taiwanese Survey; 2012. STTI.
    1. van Kleffens T, van Baarsen B, van Leeuwen E (2004) The medical practice of patient autonomy and cancer treatment refusals: a patients' and physicians' perspective. Social science & medicine 58: 2325–2336.
    1. Huijer M, van Leeuwen E (2000) Personal values and cancer treatment refusal. Journal of Medical Ethics 26: 358–362.
    1. Sensky T (2002) Withdrawal of life sustaining treatment: Patients' autonomy and values conflict with the responsibilities of clinicians. BMJ: British Medical Journal 325: 175.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi